Welcome to our dedicated page for CIRTRAN SEC filings (Ticker: CIRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CIRTRAN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CIRTRAN's regulatory disclosures and financial reporting.
CirTran Corporation (CIRX) reported another quarterly loss and remains financially distressed. For the three months ended September 30, 2025, net sales rose to $448,492 from $256,070, mainly from stronger vapor product sales, lifting gross profit to $177,826. For the nine months, revenue was broadly flat at $1,077,743, while gross profit fell to $533,062 as costs increased.
The nine‑month net loss narrowed to $1,138,064 from $1,814,150, helped by lower derivative valuation losses, but interest expense of $612,219 and a derivative loss of $34,552 still weighed on results. Cash from operations was negative $1,031,790 and was covered largely by related‑party loans of $1,051,064.
At September 30, 2025, total assets were $1.9 million against liabilities of $27.5 million, including a working capital deficit of about $22.9 million, accumulated deficit of $62.8 million, and derivative liabilities of $2.49 million. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern, and disclosure controls and procedures were deemed not effective.
CirTran Corporation (CIRX) filed a Form 12b-25 (NT 10-Q), notifying a delay in its Quarterly Report for the period ended September 30, 2025. The company states it needs additional time to compile and analyze supporting documentation and to allow its independent registered public accounting firm to complete its review of the financial statements. CirTran indicates it intends to file the Form 10-Q as soon as possible.